TRP_1170x120_12-19-19

CLARITY study demonstrating the superiority of Cosentyx (secukinumab)

Novartis Cosentyx shows superior improvements in psoriasis patients’ quality of life

Novartis Cosentyx shows superior improvements in psoriasis patients’ quality of life

BASEL — Novartis announced Tuesday additional results from the head-to-head CLARITY study demonstrating the superiority of Cosentyx (secukinumab) compared to Stelara (ustekinumab) in delivering specific quality of life (QoL) aspects in adults with moderate-to-severe plaque psoriasis at 16 weeks. New CLARITY data show over two-thirds of Cosentyx treated patients with moderate to severe psoriasis reported no impact of